Circulating microparticles in patients with antiphospholipid antibodies: Characterization and associations

Thrombosis Research

Volumn 135, Issue 1, 2015, Pages 102-108

  Chaturvedi, Shruti ^a   Cockrell, Erin ^b   Espinola, Ricardo ^c   Hsi, Linda ^a   Fulton, Stacey ^a   Khan, Mohammad ^a   Li, Liang ^a   Fonseca, Fabio ^a,e   Kundu, Suman ^a   McCrae, Keith R ^a,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b St Joseph's Heart Institute   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiphospholipid; Endothelial cell; Microparticles; Platelet; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CD14 ANTIGEN; ENDOGLIN; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LIPOCORTIN 5; PHOSPHOLIPID ANTIBODY; THROMBOPLASTIN; VASCULAR ENDOTHELIAL CADHERIN; BETA2 GLYCOPROTEIN 1; CADHERIN; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL MICROPARTICLE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MALE; MEMBRANE MICROPARTICLE; MIDDLE AGED; MONOCYTE; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROLOGY; THROMBOCYTE; VEIN PUNCTURE; CHEMISTRY; CYTOLOGY; FLOW CYTOMETRY; METABOLISM; PARTIAL THROMBOPLASTIN TIME; THROMBOSIS;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIGENS, CD; ANTIGENS, CD14; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BLOOD PLATELETS; CADHERINS; CELL-DERIVED MICROPARTICLES; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; RECEPTORS, CELL SURFACE; THROMBOPLASTIN; THROMBOSIS;

EID: 84922476881     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.11.011     Document Type: Article

References (57)

1. B. Giannakopoulos, F. Passam, S. Rahgozar, and S.A. Krilis Current concepts on the pathogenesis of the antiphospholipid syndrome Blood 109 2007 422 429
2. J.H. Rand The antiphospholipid syndrome Ann Rev Med 54 2003 409 424
3. P. Thiagarajan, and S.S. Shapiro Lupus anticoagulants and antiphospholipid antibodies Hematol Oncol Clin North Am 12 1998 1167 1192
4. S.S. Pierangeli, P.P. Chen, E. Raschi, S. Scurati, C. Grossi, and M.O. Borghi Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms Semin Thromb Hemost 34 2008 236 250
5. G. Ruiz-Irastorza, M. Crowther, W. Branch, and M.A. Khamashta Antiphospholipid syndrome Lancet 376 2010 1498 1509
6. E.M. Bevers, M. Galli, T. Barbui, P. Comfurius, and R.F.A. Zwaal Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin Thromb Haemost 66 1991 629 632
7. E. Matsuura, Y. Igarashi, M. Fujimoto, K. Ichikawa, and T. Koike Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease Lancet 335 1990 177 178
8. A. Arad, V. Proulle, R.A. Furie, B.C. Furie, and B. Furie {beta}2 glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model Blood 24 2011 3453 3459
9. Y. Ioannou, Z. Romay-Penabad, C. Pericleous, I. Giles, E. Papalardo, and G. Vargas In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept J Thromb Haemost 7 2009 833 842
10. N.L. Esmon, O. Safa, M.D. Smirnov, and C.T. Esmon Antiphospholipid antibodies and the protein C pathway J Autoimmun 15 2000 221 225
11. R.T. Urbanus, and L.B. de Antiphospholipid antibodies and the protein C pathway Lupus 19 2010 394 399
12. L.B. de, C.M. Eckmann, S.M. van, A.B. Meijer, K. Mertens, and J.A. Van Mourik Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C Blood Coagul Fibrinolysis 19 2008 757 764
13. J.H. Rand Molecular pathogenesis of the antiphospholipid syndrome Circ Res 90 2002 29 37
14. J.H. Rand, X.X. Wu, A.S. Quinn, P.P. Chen, K.R. McCrae, and E.G. Bovill Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay Am J Pathol 163 2003 1193 1200
15. R. Simantov, J.M. LaSala, S.K. Lo, A.E. Gharavi, L.R. Sammaritano, and J.E. Salmon Activation of cultured vascular endothelial cells by antiphospholipid antibodies J Clin Invest 96 1995 2211 2219
16. N. Del Papa, L. Guidala, A. Sala, C. Buccellati, M.A. Khamashta, and K. Ichikawa Endothelial cells as targets for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation Arthritis Rheum 40 1997 551 561
17. 2GPI antibodies is mediated by annexin II cross-linking, and may involve TLR4 2004 83a
18. 2-Glycoprotein I antibodies induce monocyte release of tumor necrosis factor a and tissue factor by signal transduction pathways involving lipid rafts Arthritis Rheum 56 2007 2687 2697
19. A. Lambrianides, C.J. Carroll, S.S. Pierangeli, C. Pericleous, W. Branch, and J. Rice Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways J Immunol 184 2010 6622 6628
20. T. Shi, B. Giannakopoulos, X. Yan, P. Yu, M.C. Berndt, and R.K. Andrews Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V Arthritis Rheum 54 2006 2558 2567
21. M.T. Pennings, R.H. Derksen, L.M. van, J. Adelmeijer, K. VanHoorelbeke, and R.T. Urbanus Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2' J Thromb Haemost 5 2007 369 377
22. M. Vega-Ostertag, E.N. Harris, and S.S. Pierangeli Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin Arthritis Rheum 50 2004 2911 2919
23. R.G. Espinola, X. Liu, M. Colden-Stanfield, J. Hall, E.N. Harris, and S.S. Pierangeli E-Selectin mediates pathogenic effects of antiphospholipid antibodies J Thromb Haemost 1 2003 843 848
24. 2-glycoprotein I antibodies Blood 105 2005 1964 1969
25. D.W. Branch, and G.M. Rodgers Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis Am J Obstet Gynecol 168 1993 206 210
26. K.R. McCrae, A. DeMichele, P. Samuels, D. Roth, A. Kuo, and Q. Meng Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies Br J Haematol 79 1991 595 605
27. A. Vismara, P.L. Meroni, A. Tincani, E.N. Harris, W. Barcellini, and A. Brucato Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus Clin Exp Immunol 74 1988 247 253
28. M.L. Liu, and K.J. Williams Microvesicles: potential markers and mediators of endothelial dysfunction Curr Opin Endocrinol Diabetes Obes 19 2012 121 127
29. D. Burger, S. Schock, C.S. Thompson, A.C. Montezano, A.M. Hakim, and R.M. Touyz Microparticles: biomarkers and beyond Clin Sci (Lond) 124 2013 423 441
30. A.J. Viera, M. Mooberry, and N.S. Key Microparticles in cardiovascular disease pathophysiology and outcomes J Am Soc Hypertens 6 2012 243 252
31. A.S. Leroyer, F. Anfosso, R. Lacroix, F. Sabatier, S. Simoncini, and S.M. Njock Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis Thromb Haemost 104 2010 456 463
32. P. Bucciarelli, I. Martinelli, A. Artoni, S.M. Passamonti, E. Previtali, and G. Merati Circulating microparticles and risk of venous thromboembolism Thromb Res 129 2012 591 597
33. C. Ay, J.M. Freyssinet, T. Sailer, R. Vormittag, and I. Pabinger Circulating procoagulant microparticles in patients with venous thromboembolism Thromb Res 123 2009 724 726
34. P.E. Rautou, and N. Mackman Microvesicles as risk markers for venous thrombosis Expert Rev Hematol 6 2013 91 101
35. J. Sellam, V. Proulle, A. Jungel, M. Ittah, R.C. Miceli, and J.E. Gottenberg Increased levels of circulating microparticles in primary Sjogren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity Arthritis Res Ther 11 2009 R156
36. J. Pereira, G. Alfaro, M. Goycoolea, T. Quiroga, M. Ocqueteau, and L. Massardo Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state Thromb Haemost 95 2006 94 99
37. J.I. Zwicker Predictive value of tissue factor bearing microparticles in cancer associated thrombosis Thromb Res 125 Suppl. 2 2010 S89 S91
38. J.I. Zwicker, H.A. Liebman, K.A. Bauer, T. Caughey, F. Campigotto, and R. Rosovsky Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study) Br J Haematol 160 2013 530 537
39. A.A. Khorana, C.W. Francis, K.E. Menzies, J.G. Wang, O. Hyrien, and J. Hathcock Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer J Thromb Haemost 6 2008 1983 1985
40. V. Combes, A.C. Simon, G.E. Grau, D. Arnoux, L. Camoin, and F. Sabatier In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with the lupus anticoagulant J Clin Invest 104 1999 93 102
41. A.P. Owens III, and N. Mackman Microparticles in hemostasis and thrombosis Circ Res 108 2011 1284 1297
42. K.K. Hamilton, R. Hattori, C.T. Esmon, and P.J. Simms Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex J Biol Chem 265 1990 3809 3814
43. J.G. Wang, J.C. Williams, B.K. Davis, K. Jacobson, C.M. Doerschuk, and J.P. Ting Monocytic microparticles activate endothelial cells in an IL-1beta-dependent manner Blood 118 2011 2366 2374
44. R.D. Lee, D.A. Barcel, J.C. Williams, J.G. Wang, J.C. Boles, and D.A. Manly Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity Thromb Res 129 2012 80 85
45. F. Dignat-George, L. Camoin-Jau, F. Sabatier, D. Arnoux, F. Anfosso, and N. Bardin Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome Thromb Haemost 91 2004 667 673
46. N. Del Papa, P.L. Meroni, A. Tincani, E.N. Harris, S.S. Pierangeli, and W. Barcellini Relationship between anti-phospholipid and anti-endothelial cell antibodies: further characterization of the reactivity on resting and cytokine-activated endothelial cells Clin Exp Rheumatol 10 1992 37 42
47. A. Bontadi, A. Ruffatti, E. Falcinelli, S. Giannini, A. Marturano, M. Tonello, and A. Hoxha Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome Thromb Haemost 109 2013 901 908
48. A. Vikerfors, F. Mobarrez, K. Bremme, M. Holmstrom, A. Agren, and A. Eelde Studies of microparticles in patients with the antiphospholipid syndrome (APS) Lupus 21 2012 802 805
49. W. Jy, M. Tiede, C.J. Bidot, L.L. Horstman, J.J. Jimenez, and J. Chirinos Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies Thromb Res 121 2007 319 325
50. C. Perez-Sanchez, N. Barbarroja, S. Messineo, P. Ruiz-Limon, A. Rodriguez-Ariza, and Y. Jimenez-Gomez Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus Ann Rheum Dis 2014 10 204600
51. P.G. De Groot, B. Lutters, R.H. Derksen, T. Lisman, J.C. Meijers, and F.R. Rosendaal Lupus anticoagulants and the risk of a first episode of deep venous thrombosis J Thromb Haemost 3 2005 1993 1997
52. B. de Laat, V. Pengo, I. Pabinger, J. Musial, A.E. Voskuyl, and I.E. Bultink The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study J Thromb Haemost 7 2009 1767 1773
53. V. Pengo, A. Biasiolo, T. Brocco, S. Tonetto, and A. Ruffatti Autoantibodies to phospholipid binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies Thromb Haemost 75 1996 721 724
54. 2-glycoprotein complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection Lupus 1 1992 75 81
55. X. Zhang, S.C. McGeoch, A.M. Johnstone, G. Holtrop, A.A. Sneddon, and S.M. Macrury Platelet-derived microparticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status J Thromb Thrombolysis 37 2014 455 463
56. N. Mackman, and T. Luther Platelet tissue factor: to be or not to be Thromb Res 132 2013 3 5
57. R. Willemze, R.L. Bradford, M.J. Mooberry, R.A. Roubey, and N.S. Key Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications Thromb Res 133 2014 187 189